Douglas F Lake Selected Research

sulfhydryl oxidase

1/2020	Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo.
1/2018	Correction to: Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in luminal B breast cancer.
7/2015	Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines.
3/2013	Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer.
12/2011	Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Douglas F Lake Research Topics

Disease

14	Neoplasms (Cancer) 04/2022 - 04/2003
4	Coccidioidomycosis 01/2018 - 08/2002
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 01/2016
3	Breast Neoplasms (Breast Cancer) 01/2018 - 09/2009
2	Infections 12/2021 - 12/2020
2	Pancreatic Neoplasms (Pancreatic Cancer) 12/2011 - 10/2009
2	Adenocarcinoma 12/2011 - 10/2009
2	Glioblastoma (Glioblastoma Multiforme) 09/2011 - 01/2008
1	COVID-19 12/2021
1	Neoplasm Metastasis (Metastasis) 02/2016
1	Carcinogenesis 01/2016
1	Adenocarcinoma of Lung 01/2016
1	Obesity 01/2016
1	Kidney Neoplasms (Kidney Cancer) 07/2015
1	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2014
1	Neoplasms, Cystic, Mucinous, and Serous 10/2009
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 02/2004
1	Melanoma (Melanoma, Malignant) 04/2003

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 12/2020 - 09/2009
7	Peptides (Polypeptides)IBA 01/2017 - 04/2003
5	sulfhydryl oxidaseIBA 01/2020 - 12/2011
3	matrigelIBA 01/2020 - 12/2011
3	RNA (Ribonucleic Acid)IBA 01/2017 - 12/2011
2	VaccinesIBA 12/2021 - 08/2002
2	EnzymesIBA 01/2020 - 07/2015
2	Phenobarbital (Luminal)FDA Link 01/2018 - 03/2013
2	Small Interfering RNA (siRNA)IBA 07/2015 - 12/2011
2	HLA-A*02:01 antigenIBA 09/2011 - 04/2003
2	Amino Acids FDA Link 09/2009 - 04/2003
2	AntigensIBA 04/2006 - 04/2003
1	COVID-19 VaccinesIBA 12/2021
1	Neutralizing AntibodiesIBA 12/2021
1	Antineoplastic Agents (Antineoplastics)IBA 01/2020
1	Histones (Histone)IBA 01/2019
1	Lysine (L-Lysine)FDA Link 01/2019
1	Untranslated RNA (Noncoding RNA)IBA 01/2017
1	ChromatinIBA 01/2016
1	A-Form DNA (A-DNA)IBA 01/2016
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2016
1	Muscle Proteins (Muscle Protein)IBA 01/2016
1	Nonesterified Fatty Acids (NEFA)IBA 01/2016
1	ebselenIBA 07/2015
1	DisulfidesIBA 07/2015
1	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2014
1	Indicators and Reagents (Reagents)IBA 07/2014
1	Biomarkers (Surrogate Marker)IBA 03/2013
1	GelatinIBA 03/2013
1	Estrogen ReceptorsIBA 03/2013
1	Matrix Metalloproteinases (MMPs)IBA 12/2011
1	3-Hydroxysteroid Dehydrogenases (3 beta Hydroxysteroid Dehydrogenase)IBA 09/2011
1	Chromium-51IBA 09/2011
1	BuffersIBA 09/2009
1	Histocompatibility Antigens Class IIBA 09/2009
1	Citric Acid (Citrate)FDA LinkGeneric 09/2009
1	PapainIBA 09/2009
1	AcidsIBA 09/2009
1	Mannose ReceptorIBA 04/2005
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 02/2004
1	Insulin (Novolin)FDA Link 02/2004
1	AutoantigensIBA 02/2004
1	EpitopesIBA 04/2003
1	Peptide LibraryIBA 04/2003

Therapy/Procedure

3	Therapeutics 04/2022 - 08/2002
1	Oral Administration 01/2020
1	Precision Medicine 01/2019
1	Drug Therapy (Chemotherapy) 02/2016